Company intelligence / Profile preview

CrossBridge Bio

Houston, Texas, United Statescrossbridgebio.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

No active clinical trials found on ClinicalTrials.gov. The company is advancing its lead program CBB-120, a potential best-in-class TROP2 ADC for certain breast cancers and other TROP2-positive cancers.

Therapeutic areas: Oncology
Modalities: Antibody-Drug Conjugates (ADCs)Dual-payload ADCs
Industry: Biotech

Drug pipeline

1 asset

CBB-120

Preclinical

Beyond the preview

Go deeper on CrossBridge Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CrossBridge Bio.

Explore the full profile